Toward imaging of alpha-synuclein with PET

Development of radiopharmaceuticals for in vivo positron emission tomography imaging of alpha-synuclein aggregates has the potential to revolutionize Lewy body disease diagnosis and treatment. Reporting in this issue of Cell, Xiang et al. developed a high-affinity positron emission tomography tracer for alpha-synuclein. Development of radiopharmaceuticals for in vivo positron emission tomography imaging of alpha-synuclein aggregates has the potential to revolutionize Lewy body disease diagnosis and treatment. Reporting in this issue of Cell, Xiang et al. developed a high-affinity positron emission tomography tracer for alpha-synuclein. Development of an α-synuclein positron emission tomography tracer for imaging synucleinopathiesXiang et al.CellJuly 7, 2023In BriefDevelopment and structural characterization of a specific, high-affinity α-synuclein PET tracer for synucleinopathy imaging. Full-Text PDF